ArticleImmunotherapy2020
Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins.
Open access · hybridAbstract read
In one paragraph
Article in Immunotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
0.9field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 41 citations in OpenAlex.
- COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain.The Journal of clinical investigation · 2020Trial
- Homologous MVA and heterologous DREP/MVA vaccine regimens induce robust and durable immune responses against SARS-CoV-2.Scientific reports · 2026Article
- Long-term immunity and protection against SARS-CoV-2 XBB.1.5 following homologous and heterologous mRNA and MVA vaccination.Frontiers in immunology · 2026Article
- Immunogenicity and efficacy of homologous and heterologous NDV and MVA SARS-CoV-2 vaccines in mice and hamsters.NPJ vaccines · 2025Article
- Host factor PLAC8 is required for pancreas infection by SARS-CoV-2.Communications medicine · 2025Article
- Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium.NPJ vaccines · 2024Article
- MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses.Frontiers in immunology · 2024Article
- Comparative SARS-CoV-2 Omicron BA.5 variant and D614G-Wuhan strain infections in ferrets: insights into attenuation and disease progression during subclinical to mild COVID-19.Frontiers in veterinary science · 2024Article
- Contribution of immunoglobulin products in influencing seasonal influenza infection and severity in antibody immune deficiency patients receiving immunoglobulin replacement therapy.Frontiers in immunology · 2024Review
- Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates.Frontiers in immunology · 2023Article
- Article
- Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters.Frontiers in immunology · 2023Article
- Pulsed-Xenon Ultraviolet Light Highly Inactivates Human Coronaviruses on Solid Surfaces, Particularly SARS-CoV-2.International journal of environmental research and public health · 2022Article
- Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins.The Journal of infectious diseases · 2022Article
- Effective presence of antibodies against common human coronaviruses in immunoglobulin medicinal products.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Article
- Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice.NPJ vaccines · 2022Article
- Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.Frontiers in immunology · 2022Article
- SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022Article
- Immune response and potential therapeutic strategies for the SARS-CoV-2 associated with the COVID-19 pandemic.International journal of biological sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
José María DíezBioscience Research & Development, Grifols, Barcelona, Spain.
Carolina RomeroBioscience Research & Development, Grifols, Barcelona, Spain.
Júlia Vergara-AlertIRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona (UAB), Bellaterra, Barcelona, Spain.
Melissa Belló-PerezLaboratorio Coronavirus. Departamento de Biología Molecular y Celular, CNB-CSIC, Madrid, Spain.
Jordi RodonIRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona (UAB), Bellaterra, Barcelona, Spain.
José Manuel HonrubiaLaboratorio Coronavirus. Departamento de Biología Molecular y Celular, CNB-CSIC, Madrid, Spain.
Joaquim SegalésUAB, CReSA (IRTA-UAB), Campus de la Universitat Autònoma de Barcelona (UAB), Bellaterra, Barcelona, Spain.
Isabel SolaLaboratorio Coronavirus. Departamento de Biología Molecular y Celular, CNB-CSIC, Madrid, Spain.
Luis EnjuanesLaboratorio Coronavirus. Departamento de Biología Molecular y Celular, CNB-CSIC, Madrid, Spain.
Rodrigo GajardoBioscience Research & Development, Grifols, Barcelona, Spain.
Consejo Superior de Investigaciones Científicas · ESGrifols (Spain) · ESUniversitat Autònoma de Barcelona · ESCentre de Recerca en Sanitat Animal · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antibodies, NeutralizingAntibodies, ViralBetacoronavirusCoronavirus InfectionsCOVID-19Cross ReactionsHumansImmunoglobulins, IntravenousMiddle East Respiratory Syndrome CoronavirusPandemicsPneumonia, ViralSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralImmunoglobulins, IntravenousCOVID-19cross-neutralizationintravenous immunoglobulinMERS-CoVSARS-CoVSARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.